ARTICLE | Top Story
Rebif tops Avonex at 24 weeks
May 8, 2001 7:00 AM UTC
Serono (SRA; SWX: SEO) said that in the single-blind EVIDENCE trial comparing its Rebif interferon beta-1a to Avonex interferon beta-1a in 677 patients with replapsing-remitting multiple sclerosis (RR...